These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31797633)

  • 21. The use of PanDrugs to prioritize anticancer drug treatments in a case of T-ALL based on individual genomic data.
    Fernández-Navarro P; López-Nieva P; Piñeiro-Yañez E; Carreño-Tarragona G; Martinez-López J; Sánchez Pérez R; Aroca Á; Al-Shahrour F; Cobos-Fernández MÁ; Fernández-Piqueras J
    BMC Cancer; 2019 Oct; 19(1):1005. PubMed ID: 31655559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
    Gerhards NM; Rottenberg S
    Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma.
    Berlow NE; Rikhi R; Geltzeiler M; Abraham J; Svalina MN; Davis LE; Wise E; Mancini M; Noujaim J; Mansoor A; Quist MJ; Matlock KL; Goros MW; Hernandez BS; Doung YC; Thway K; Tsukahara T; Nishio J; Huang ET; Airhart S; Bult CJ; Gandour-Edwards R; Maki RG; Jones RL; Michalek JE; Milovancev M; Ghosh S; Pal R; Keller C
    BMC Cancer; 2019 Jun; 19(1):593. PubMed ID: 31208434
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A combined tissue-engineered/in silico signature tool patient stratification in lung cancer.
    Göttlich C; Kunz M; Zapp C; Nietzer SL; Walles H; Dandekar T; Dandekar G
    Mol Oncol; 2018 Aug; 12(8):1264-1285. PubMed ID: 29797762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Precision medicine for suicidality: from universality to subtypes and personalization.
    Niculescu AB; Le-Niculescu H; Levey DF; Phalen PL; Dainton HL; Roseberry K; Niculescu EM; Niezer JO; Williams A; Graham DL; Jones TJ; Venugopal V; Ballew A; Yard M; Gelbart T; Kurian SM; Shekhar A; Schork NJ; Sandusky GE; Salomon DR
    Mol Psychiatry; 2017 Sep; 22(9):1250-1273. PubMed ID: 28809398
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Matching cancer genomes to established cell lines for personalized oncology.
    Dudley JT; Chen R; Butte AJ
    Pac Symp Biocomput; 2011; ():243-52. PubMed ID: 21121052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Personalized Network Modeling of the Pan-Cancer Patient and Cell Line Interactome.
    Bhattacharyya R; Ha MJ; Liu Q; Akbani R; Liang H; Baladandayuthapani V
    JCO Clin Cancer Inform; 2020 May; 4():399-411. PubMed ID: 32374631
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A computational method for clinically relevant cancer stratification and driver mutation module discovery using personal genomics profiles.
    Wang L; Li F; Sheng J; Wong ST
    BMC Genomics; 2015; 16 Suppl 7(Suppl 7):S6. PubMed ID: 26099165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modeling gene-wise dependencies improves the identification of drug response biomarkers in cancer studies.
    Nikolova O; Moser R; Kemp C; Gönen M; Margolin AA
    Bioinformatics; 2017 May; 33(9):1362-1369. PubMed ID: 28082455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RefDNN: a reference drug based neural network for more accurate prediction of anticancer drug resistance.
    Choi J; Park S; Ahn J
    Sci Rep; 2020 Feb; 10(1):1861. PubMed ID: 32024872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DROEG: a method for cancer drug response prediction based on omics and essential genes integration.
    Wu P; Sun R; Fahira A; Chen Y; Jiangzhou H; Wang K; Yang Q; Dai Y; Pan D; Shi Y; Wang Z
    Brief Bioinform; 2023 Mar; 24(2):. PubMed ID: 36715269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Colorectal Cancer Cell Line Proteomes Are Representative of Primary Tumors and Predict Drug Sensitivity.
    Wang J; Mouradov D; Wang X; Jorissen RN; Chambers MC; Zimmerman LJ; Vasaikar S; Love CG; Li S; Lowes K; Leuchowius KJ; Jousset H; Weinstock J; Yau C; Mariadason J; Shi Z; Ban Y; Chen X; Coffey RJC; Slebos RJC; Burgess AW; Liebler DC; Zhang B; Sieber OM
    Gastroenterology; 2017 Oct; 153(4):1082-1095. PubMed ID: 28625833
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective molecular profiling of canine cancers provides a clinically relevant comparative model for evaluating personalized medicine (PMed) trials.
    Paoloni M; Webb C; Mazcko C; Cherba D; Hendricks W; Lana S; Ehrhart EJ; Charles B; Fehling H; Kumar L; Vail D; Henson M; Childress M; Kitchell B; Kingsley C; Kim S; Neff M; Davis B; Khanna C; Trent J
    PLoS One; 2014; 9(3):e90028. PubMed ID: 24637659
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pan-Cancer Prediction of Cell-Line Drug Sensitivity Using Network-Based Methods.
    Pouryahya M; Oh JH; Mathews JC; Belkhatir Z; Moosmüller C; Deasy JO; Tannenbaum AR
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of drug response in multilayer networks based on fusion of multiomics data.
    Yu L; Zhou D; Gao L; Zha Y
    Methods; 2021 Aug; 192():85-92. PubMed ID: 32798653
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predict drug sensitivity of cancer cells with pathway activity inference.
    Wang X; Sun Z; Zimmermann MT; Bugrim A; Kocher JP
    BMC Med Genomics; 2019 Jan; 12(Suppl 1):15. PubMed ID: 30704449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identifying subpathway signatures for individualized anticancer drug response by integrating multi-omics data.
    Xu Y; Dong Q; Li F; Xu Y; Hu C; Wang J; Shang D; Zheng X; Yang H; Zhang C; Shao M; Meng M; Xiong Z; Li X; Zhang Y
    J Transl Med; 2019 Aug; 17(1):255. PubMed ID: 31387579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world performance analysis of a novel computational method in the precision oncology of pediatric tumors.
    Vodicska B; Déri J; Tihanyi D; Várkondi E; Kispéter E; Dóczi R; Lakatos D; Dirner A; Vidermann M; Filotás P; Szalkai-Dénes R; Szegedi I; Bartyik K; Gábor KM; Simon R; Hauser P; Péter G; Kiss C; Garami M; Peták I
    World J Pediatr; 2023 Oct; 19(10):992-1008. PubMed ID: 36914906
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Computational modeling of early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) to identify personalized therapy using genomics.
    Kumar A; Drusbosky LM; Meacham A; Turcotte M; Bhargav P; Vasista S; Usmani S; Pampana A; Basu K; Tyagi A; Lala D; Rajagopalan S; Birajdar SC; Alam A; Ghosh Roy K; Abbasi T; Vali S; Sengar M; Chinnaswamy G; Shah BD; Cogle CR
    Leuk Res; 2019 Mar; 78():3-11. PubMed ID: 30641417
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.